Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Published bySinikka Härkönen Modified over 5 years ago

Similar presentations

Presentation on theme: "The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,"— Presentation transcript:

1 The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma 
Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko, MD, PhD, Masato Katahira, MD, Mitsumasa Osakabe, MD, PhD, Shin-ya Ogata, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 11, Pages (November 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 The recurrence-free survival curve (A) and the overall survival curve (B) according to the predominant histopathological patterns in all stages (N = 531). The recurrence-free survival and overall survival differed significantly among the predominant histopathological patterns (p < 0.01 and p < 0.01, respectively). Lepidic means lepidic adenocarcinoma with adenocarcinoma in situ and minimally invasive adenocarcinoma. IMA, invasive mucinous adenocarcinoma. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 The recurrence-free survival curve (A) and the overall survival curve (B) according to the five subgroups in all stages (N = 531). The recurrence-free survival and overall survival differed significantly among the five subgroups (p < 0.01 and p < 0.01, respectively). S–, solid pattern absent; MP –, micropapillary pattern absent; S+ not pre, solid pattern present but not predominant; MP+ not pre, micropapillary pattern present but not predominant; S pre, solid predominant pattern; MP pre, micropapillary predominant pattern. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 The recurrence-free survival curve (A) and the overall survival curve (B) according to the five subgroups in patients with stage I disease (N = 420). The recurrence-free survival and overall survival differed significantly among the five subgroups (p < 0.01 and p < 0.01, respectively). S–, solid pattern absent; MP –, micropapillary pattern absent; S+ not pre, solid pattern present but not predominant; MP+ not pre, micropapillary pattern present but not predominant; S pre, solid predominant pattern; MP pre, micropapillary predominant pattern. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma  Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,"

Similar presentations

The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS)

The Correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS)
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma  Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma  Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Results of Surgical Treatment for Patients with Small Cell Lung Cancer
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience  Ramsey Asmar, MD, Joshua R. Sonett, MD,

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience  Ramsey Asmar, MD, Joshua R. Sonett, MD,
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma  Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.
Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.
Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for.

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for.
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Similar presentations

Ads by Google